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Abstract 
Purpose: The aggressiveness of pancreatic ductal adenocarcinoma (PDAC) is highly dependent on the level of 
differentiation and the composition of the stroma. In this preclinical study, we investigated the potential of diffusion‑
weighted magnetic resonance imaging (DW‑MRI) and dynamic contrast‑enhanced magnetic resonance imaging 
(DCE‑MRI) as noninvasive methods for providing information on the differentiation and the stroma of PDACs.
Methods: Xenografted tumors initiated from four PDAC cell lines (BxPC‑3, Capan‑2, MIAPaCa‑2, and Panc‑1) were 
included in the study. DW‑MRI and DCE‑MRI were carried out on a 7.05‑T MR scanner, and tumor images of ADC (the 
apparent diffusion coefficient), Ktrans (the volume transfer constant of Gd‑DOTA), and ve (the fractional distribution vol‑
ume of Gd‑DOTA) were produced. The level of differentiation and the amount and structure of collagen I and collagen 
IV were determined by examining histological preparations.
Results: Differentiated tumors showed lower levels of collagen I and collagen IV than non‑differentiated tumors. Sig‑
nificant correlations were found between ADC and ve, and both parameters differentiated clearly between collagen‑
rich non‑differentiated tumors and differentiated tumors containing less collagen.
Conclusion: Differentiated PDAC xenografts show higher ADC values and higher ve values than their non‑differenti‑
ated counterparts. This observation supports the application of parametric MR images as tumor biomarkers in PDAC. 
Patients showing low values of ADC and ve most likely have non‑differentiated tumors with extensive stroma and, 
hence, poor prognosis.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly 
aggressive disease with poor prognosis. The majority of 
the patients are subjected to chemotherapy, which only 
marginally increases their lifespan [1]. Aggressive growth 
and treatment resistance are associated with poor differ-
entiation and extensive tumor stroma in PDAC [1–4].
The stromal component is a defining characteristic of 
PDAC, constituting the majority of the tumor volume [5]. 
In addition to fibroblasts and immune cells, it is charac-
terized by an often dense extracellular matrix [6]. Stro-
mal fibroblasts promote local invasion [4, 7], and several 
components of the extracellular matrix have been shown 
to decrease the cytotoxicity of anticancer drugs in pan-
creatic cancer cell lines [8]. The stroma has also been 
postulated to serve as a mechanistic barrier to chemo-
therapy [9]. Collagen is a major component of the stroma, 
and collagen I is highly up-regulated in PDAC [10]. Both 
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power, and high levels of these matrix components are 
associated with poor survival rates [11, 12].
The composition of the stroma is associated with the 
level of differentiation in PDAC, and patients with poorly 
differentiated tumors have worse prognosis than those 
with well differentiated tumors [13]. Radiological stud-
ies attempting to use diffusion-weighted magnetic reso-
nance imaging (DW-MRI) or dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI) to distinguish 
between well and poorly differentiated PDACs have given 
conflicting results [14–19]. Highly different protocols 
were used for image acquisition and analysis in these 
investigations, and consequently, comparisons of obser-
vations are difficult. Moreover, these investigations have 
severe limitations. First, the MRI was carried out under 
suboptimal conditions in some investigations, and other 
investigations suffer from inadequate image analysis. Sec-
ond, DW-MRI and DCE-MRI were not performed on the 
same patient cohorts, and the collagen component of the 
imaged tissue was not assessed.
MRI can be carried out under well-controlled condi-
tions in preclinical studies, and the tumor tissue can be 
excised in its entirety immediately after the imaging for 
histological examination. Experimental tumors should 
therefore be useful for investigating whether DW-MRI 
and DCE-MRI, either separately or in combination, may 
have the power to distinguish between poorly and well 
differentiated PDACs. The possibility that DW-MRI and 
DCE-MRI can provide images reflecting the histological 
appearance of PDACs was examined in detail in the pre-
clinical study reported here. By subjecting PDAC xeno-
grafts to DW-MRI, DCE-MRI, and detailed histological 
examinations, we provide strong evidence that paramet-
ric images derived from DW-MRI and DCE-MRI data 
can distinguish collagen-rich non-differentiated tumors 
from differentiated tumors with less collagen.
Methods
Tumor models
BxPC-3, Capan-2, MIAPaCa-2, and Panc-1 (American 
Type Culture Collection, VA, USA) human PDAC xeno-
grafts grown in adult (8–12 weeks of age) female BALB/c 
nu/nu mice were used as preclinical tumor models. 
Tumors were initiated from cells cultured in RPMI-1640 
(25  mmol/l HEPES and l-glutamine) medium supple-
mented with 13  % bovine calf serum, 250  mg/l penicil-
lin, and 50 mg/l streptomycin. Approximately 2.5 × 106 
cells in 20–30  μl of Hanks’ balanced salt solution were 
inoculated in the gastrocnemius muscle. Tumors with 
volumes of 400–1200  mm3 were included in the study. 
Tumor volume was determined from MR images, and 
tumor volume doubling time (Td) was calculated as 
Td = t × ln2
/
(lnVt − lnV0), where t = time from tumor 
cell inoculation to MR scanning, Vt  =  tumor volume 
at time of scanning, and V0 =  tumor volume at time of 
cell inoculation (set to 1  mm3). The tumors of all mod-
els showed only negligible regions with necrotic, cystic, 
or hemorrhagic tissue. The animal experiments were 
approved by the Institutional Committee on Research 
Animal Care and were performed according to the Inter-
disciplinary principles and guidelines for the use of ani-
mals in research, marketing, and education (New York 
Academy of Sciences, New York, NY, USA).
Magnetic resonance imaging
MRI was carried out at the MRI Core Facility for Pre-
clinical Cancer Research, Oslo University Hospital, by 
using a Bruker Biospec 7.05-T bore magnet and a mouse 
quadrature volume coil (Bruker Biospin, Ettlingen, Ger-
many). Twelve BxPC-3, 12 Capan-2, 12 MIAPaCa-2, and 
16 Panc-1 tumors were subjected to MRI, and DCE-MRI 
was carried out immediately after DW-MRI. The tumors 
were positioned in the isocenter of the magnet and were 
imaged with 7–8 axial slices covering the entire volume. 
The mice were given gas anesthesia (~4.0  % Sevofluran 
in O2; Baxter, IL, USA) at a flow rate of 0.5  l/min dur-
ing imaging. Respiration rate and body core temperature 
were monitored continuously by using an abdominal 
pressure sensitive probe and a rectal temperature probe 
(Small Animal Instruments, New York, NY, USA). The 
body core temperature was kept at 37  °C by automated 
hot air flow regulation, and the gas anesthesia was 
adjusted manually to maintain a stable respiration rate. 
Anatomical T2-weighted images were obtained prior 
to DW-MRI and DCE-MRI by using a fast spin echo 
pulse sequence (RARE) with a repetition time (TR) of 
2500  ms, an echo time (TE) of 35  ms, an image matrix 
of 128 × 128, a field of view (FOV) of 3 × 3 cm2, a slice 
thickness of 0.7  mm, a slice gap of 0.3  mm, 2 averages, 
and fat suppression.
DW-MRI was carried out as described previously [20]. 
Briefly, we applied a diffusion-weighted single-shot fast 
spin echo pulse sequence (RARE) with a TR of 1300 ms, 
a TE of 26  ms, an image matrix of 64  ×  64, a FOV of 
3  ×  3  cm2, a slice thickness of 0.7  mm, a slice gap of 
0.3  mm, and fat suppression. Four diffusion-weightings 
with diffusion encoding constants (b) of 200, 400, 700, 
and 1000  s/mm2, a diffusion gradient duration of 7  ms, 
and a diffusion separation time of 14 ms were used. Val-
ues of b ranging from 200 to 1000 s/mm2 were chosen to 
avoid perfusion effects [21, 22]. Diffusion sensitization 
gradients were applied in three orthogonal directions, 
and ADC values were calculated for each direction by 
using in-house-made software developed in Matlab 
(MathWorks, Natick, MA, USA). Furthermore, the direc-
tional diffusion images were averaged on a voxel-by-voxel 
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basis to non-directional diffusion images, and these non-
directional images were used to calculate ADC maps. 
As expected for isotropic tumors, the ADC values were 
found to be independent of the direction of the diffusion 
sensitization gradients (Additional file 1: Figure S1).
DCE-MRI with Gd-DOTA (Dotarem, Guerbet, Paris, 
France) as contrast agent was performed as described 
earlier [20]. Briefly, a fast spin echo pulse sequence 
(RARE) with TRs of 200, 400, 800, 1500, 3000, and 
5000 ms, a TE of 8.5 ms, an image matrix of 128 × 128, 
a FOV of 3 × 3 cm2, a slice thickness of 0.7 mm, and a 
slice gap of 0.3 mm was applied to measure precontrast 
T1-values (T10-map). Gd-DOTA was diluted to a concen-
tration of 0.06  M and administered in the tail vein in a 
bolus dose of 5.0 ml/kg body weight during a period of 
5 s by using an automated infusion pump (Harvard Ap-
paratus, Holliston, MA, USA). A three-dimensional 
SPGR pulse sequence (3D-FLASH) with a TR of 10 ms, 
a TE of 2.07 ms, a flip angle (α) of 20°, an image matrix of 
128 × 128, and a FOV of 3 × 3 cm2 was used to produce 
dynamic T1-weighted images at a temporal resolution of 
14.8 s. Numerical values of the volume transfer constant 
(Ktrans) and the fractional distribution volume (ve) of the 
contrast agent were determined on a voxel-by-voxel basis 
by using the Tofts pharmacokinetic model [23]. Calcu-
lation of Gd-DOTA concentrations and pharmacoki-
netic modeling were done with in-house-made software 
developed in Matlab (MathWorks). Representative plots 
of Gd-DOTA concentration versus time and the cor-
responding curve fits are presented in Fig. 1, illustrating 
that good fits were obtained for single voxels with highly 
different uptake of Gd-DOTA. The intratumor heteroge-
neity in Ktrans and ve was substantial, and to ensure that 
our DCE-MRI method provided high-quality Ktrans and 
ve images, it was verified that structural tumor elements 
were clearly recognizable in parametric images of ad-
jacent slices (Additional file 1: Figure S2).
The analysis of the DW-MRI and DCE-MRI data was 
based the entire volume of the tumors without includ-
ing peritumoral blood vessels. Regions of interest (ROIs) 
encompassing the tumor tissue were depicted in the T2-
weighted anatomical images acquired prior to the DW-
MRI, and these ROIs were transferred to the DW and 
DCE images (Fig. 2). The quantitative analyses were car-
ried out on these ROIs without excluding any voxels. It 
was verified that the tumors did not move between imag-
ing sequences or during imaging series (Fig. 2), and con-
sequently, motion correction algorithms were not used.
Histological examinations
Histological sections were cut from three different 
positions in each tumor and stained with hematoxy-
lin and eosin (HE) by using a standard procedure or 
immunostained for connective tissue by using a per-
oxidase-based indirect staining method [24]. An anti-
collagen I rabbit polyclonal antibody (ab34710, Abcam, 
Cambridge, UK) or an anti-collagen IV rabbit polyclonal 
antibody (ab6586, Abcam) was used as primary anti-
body. Diaminobenzidine was used as chromogen, and 
hematoxylin was used for counterstaining. Tumor differ-
entiation was determined from HE stained sections and 
classified on a scale from 1 to 4, where 1 refers to non-
differentiated tumors and 4 refers to well differentiated 
tumors. The extent of collagen I and collagen IV staining 
was assessed semiquantitatively by using a scale from 0 
to 4, where 0 and 4 represent no staining and maximal 
staining, respectively.
Statistical analysis
The Pearson product moment correlation test was used 
to search for correlations between parameters. Statisti-
cal comparisons of data sets were carried out by using 
the Student’s t test when the data sets complied with the 
conditions of normality and equal variance. Under other 
conditions, comparisons were carried out by nonpara-
metric analysis using the Mann–Whitney rank-sum test. 
Probability values of P < 0.05, determined from two-sided 
tests, were considered significant. The SigmaStat statisti-
cal software (SPSS Science, Chicago, IL, USA) was used 
for the statistical analysis.
Results
The four PDAC tumor models differed considerably in 
histological appearance. The BxPC-3 and Capan-2 mod-
els were differentiated and showed distinct ductal struc-
tures (Fig.  3a, b), whereas the MIAPaCa-2 and Panc-1 
models were non-differentiated and showed an appar-
ently random distribution of the tumor cells (Fig. 3c, d). 
The tumor models differed notably also in the amount 
and distribution of collagen I and collagen IV. In the 
differentiated models, collagen I and IV were found 
in thick filament bundles separating clusters of tumor 
cells (Fig.  3a, b), whereas the non-differentiated mod-
els showed a strikingly divergent collagen arrangement 
with thin fibers of collagen I and IV surrounding single 
tumor cells (Fig. 3c, d). On the other hand, the individ-
ual tumors of each PDAC model did not differ in differ-
entiation or collagen staining. In fact, they could not be 
distinguished from each other, regardless of whether HE 
stained or immunostained sections were examined and 
regardless of whether the sections were prepared from 
central or peripheral regions of the tumors.
Semiquantitative analysis revealed that the two differ-
entiated PDAC models showed only minor differences 
in collagen content even though BxPC-3 was clearly 
less differentiated than Capan-2, and furthermore, the 
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difference in collagen content between the two non-dif-
ferentiated PDAC models was also small (Fig. 4a, c). On 
the other hand, the content of collagen was clearly higher 
in the non-differentiated models than in the differenti-
ated models, and the difference was particularly large 
for collagen IV. Interestingly, the volume doubling times 
of the MIAPaCa-2 and Panc-1 tumors were significantly 
longer than those of the BxPC-3 and Capan-2 tumors 
(Fig. 4d; P < 0.001); in other words, the tumors of the dif-
ferentiated PDAC models grew faster than those of the 
non-differentiated models.
ADC, ve, and Ktrans images and frequency distribu-
tions of a representative tumor of each PDAC model are 
shown in Fig.  5. The intratumor heterogeneity in these 
MR parameters was substantial in all four PDAC models. 
In general, the tumors showed higher Ktrans values in the 
periphery than in central regions, whereas the highest 
values of ve and ADC were more randomly distributed 
within the tumor volume. This observation emphasizes 
the importance of analyzing the entire tumor volume, as 
was done here. Furthermore, Fig. 5 shows that the shape 
of the frequency distributions of ADC, ve, and Ktrans dif-
fered among individual tumors. In some tumors, these 
parameters showed frequency distributions that were 
far from Gaussian, and consequently, the median value 
of each parameter rather than the mean value was calcu-
lated for each tumor and used in the further analysis.
The MR parameters were found to differ significantly 
among the PDAC models (Fig.  6a). Compared with the 
non-differentiated models, the differentiated models 
Fig. 1 Pharmacokinetic analysis of representative tumors. Plots of Gd‑DOTA concentration versus time (symbols) and the corresponding curve fits 
(solid lines) for single voxels of a BxPC‑3 (a), Capan‑2 (b), MIAPaCa‑2 (c), and Panc‑1 (d) tumor. The Ktrans and ve values of the voxels were determined 
by the Tofts pharmacokinetic model, and are shown in the panels in the same color as the corresponding curve
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showed higher values of ADC (P < 0.001) and higher val-
ues of ve (P < 0.001), whereas the differences in Ktrans were 
not associated with the level of differentiation. Further-
more, significant correlations were found between the 
different MR parameters (Fig. 6b). Thus, ADC was posi-
tively correlated to ve (P < 0.001) and Ktrans (P < 0.001), 
and Ktrans was positively correlated to ve (P < 0.001). Sig-
nificant correlations were also found between the MR 
parameters and tumor growth rate (Fig. 6c); ADC, ve, and 
Ktrans decreased with increasing tumor volume doubling 
time (P < 0.001 for all parameters).
Discussion
The possibility that DW-MRI and/or DCE-MRI may be 
useful noninvasive methods for providing information 
on the level of differentiation in PDAC was investigated 
in this preclinical study by performing experiments with 
four xenograft models of PDAC. Preclinical investiga-
tions have the advantage to clinical investigations that 
several copies of the same patient’s tumor can be studied. 
The individual xenografted tumors of the same PDAC 
model were initiated from the same cell line in this study, 
and consequently, these tumors were genetically equal 
and represent a single human tumor. These tumors were 
for the same reason indistinguishable histologically, both 
in HE stained and immunostained preparations. How-
ever, individual tumors of the same model may differ 
somewhat in vascular density and blood perfusion for 
two main reasons. First, tumor vascularity decreases with 
increasing tumor size in most experimental tumors, pri-
marily because the tumor parenchyma outgrows the vas-
cular network [25]. Second, stochastic processes involved 
in tumor angiogenesis may lead to differences in vascular 
density and blood perfusion between individual tumors 
of the same model [26]. Therefore, median ADC, Ktrans, 
and ve differed among the individual tumors of the same 
PDAC model in this study, but these differences were 
small compared with the differences between the four 
models. Human PDACs may show substantial intratumor 
heterogeneity in vascularity and, hence, in parametric 
Fig. 2 MR images of a representative tumor. T2‑weighted anatomical image (a) and T1‑weighted images (b–h) from an experiment with a BxPC‑3 
tumor. The T1‑weighted images were recorded with a fast spin echo pulse sequence for calculation of precontrast T1 values (b) or with a three‑
dimensional SPGR sequence for acquiring dynamic series (c–h). Dynamic images were recorded before and every 14.8 s after contrast adminis‑
tration. The dynamic images in (c–h) refer to a precontrast image (c, d) and images recorded 1 min (e), 5 min (f), 10 min (g), and 15 min (h) after 
contrast administration. The region within the square in (c) is highlighted in (d–h). Tumor regions of interest (ROI) were depicted in the anatomical 
image (a) and were transferred to the other images since the different pulse sequences were performed with identical geometrical settings. The 
tumor ROI is outlined with black in the images (a–h). The coordinates of the tumor voxels are defined by the white grids (one line per 20 voxels) in 
(d–h). The images illustrate that the tumor did not move or change shape during the MRI. Scale bars 5 mm
Page 6 of 11Wegner et al. J Transl Med  (2016) 14:161 
MR images, and this intratumor heterogeneity may be 
captured in preclinical studies involving several tumors 
of the same model.
The four preclinical tumor models included in this 
study differed highly in structural appearance and rep-
resent two clinically important groups of PDAC, differ-
entiated and non-differentiated tumors. In agreement 
with earlier findings, Capan-2 and BxPC-3 were shown 
to be differentiated, whereas MIAPaCa-2 and Panc-1 
were found to be non-differentiated [27]. Moreover, 
the non-differentiated models were found to have more 
collagen I and collagen IV and a more densely packed 
matrix of collagen fibers than the differentiated models. 
Because both poor differentiation and a high level of col-
lagen fibers are associated with poor prognosis in PDAC 
[11–13], xenografted BxPC-3, Capan-2, MIAPaCa-2, and 
Panc-1 tumors should be well-suited preclinical models 
for providing clinically relevant answers to the questions 
addressed in the present MRI study.
The DCE-MRI data were analyzed by using the Tofts 
pharmacokinetic model [23]. This model is based on sev-
eral assumptions. The most important of these are that 
the interstitial concentration of contrast agent is uniform 
within the voxels, that the contribution of intravascular 
contrast agent to the total tumor concentration can be 
ignored, and that any effects of water exchange are insig-
nificant [23]. When these assumptions are adequately 
fulfilled, Ktrans is determined by the blood flow and the 
permeability of the vessel wall, and ve is determined by 
the fractional distribution volume of the contrast agent 
in the tumor tissue [28]. The Tofts model gave good fits 
to our experimental data at the single voxel level in all 
four PDAC models, suggesting that this pharmacoki-
netic model is suitable for analyzing the DCE-MRI data 
recorded in this study. Other more complex pharma-
cokinetic models are also being used frequently, includ-
ing the Brix model [29] and the shuttle speed model [30]. 
Comparative studies of the usefulness of these models 
in the analysis of human DCE-MRI data have suggested 
that the Tofts model is preferable to the more complex 
pharmacokinetic models [31]. Furthermore, a consensus 
meeting involving MR scientists from several institutions 
has recommended the Tofts models for analysis of pre-
clinical and clinical DCE-MRI series [28].
Fig. 3 Differentiated and non‑differentiated PDAC tumor models. Histological preparations of a BxPC‑3 (a), Capan‑2 (b), MIAPaCa‑2 (c), and Panc‑1 
(d) tumor. Arrows point to ductal structures seen in the two differentiated models, BxPC‑3 and Capan‑2. The non‑differentiated models MIAPaCa‑2 
and Panc‑1 did not show ductal structures. Scale bars 100 µm. Upper panels HE staining. Middle panels Collagen I staining. Lower panels Collagen IV 
staining
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Our study showed that ADC was higher in the differ-
entiated than in the non-differentiated PDAC models. 
Most likely, this difference was partly a consequence 
of the difference in the density of the extracellular col-
lagen matrix and partly a consequence of the presence 
of ductal structures with central cavities in the differ-
entiated tumors. ADC is a measure of water diffusion 
[32, 33] and has been shown to decrease with increas-
ing cell density [34]. The low cell density associated with 
the ductal structures of the differentiated tumors prob-
ably restricted the diffusion of water to a lesser extent 
than the densely packed cells of the non-differentiated 
tumors, thus contributing to the differences seen in 
ADC. Furthermore, collagen has been shown to impede 
water diffusion [22, 35]. Because the collagen network of 
the differentiated tumors primarily surrounded clusters 
of tumor cells whereas that of the non-differentiated 
tumors primarily surrounded single cells, the collagen 
network may have restricted the diffusion of water to 
a lesser extent in the differentiated tumors than in the 
non-differentiated tumors, thus contributing to the 
observed differences in ADC.
Also ve was found to be higher in the differentiated than 
in the non-differentiated PDAC models. This parameter 
is a measure of the distribution volume of the contrast 
agent and is determined by the fractional volume of the 
extravascular extracellular space and the density of the 
extracellular matrix [28]. Consequently, the differences 
between the differentiated and non-differentiated tumors 
in cell density and collagen content, particularly col-
lagen IV, most likely contributed to the differences in ve 
detected here.
Fig. 4 Differentiated PDAC tumor models have less collagen and grow faster than non‑differentiated PDAC tumor models. Level of differentia‑
tion (a), amount of collagen I (b), amount of collagen IV (c), and volume doubling time (d) of BxPC‑3, Capan‑2, MIAPaCa‑2, and Panc‑1 tumors. The 
individual tumors of the same model were indistinguishable histologically in both HE stained and immunostained sections, but differed in growth 
rate. Columns and bars in (d) Mean ± SEM of 12–16 tumors
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Fig. 5 Images and frequency distributions of MR parameters of differentiated and non‑differentiated PDAC tumor models. ADC, ve, and K
trans 
images and frequency distributions of a representative BxPC‑3 (a), Capan‑2 (b), MIAPaCa‑2 (c), and Panc‑1 (d) tumor, illustrating that the intratumor 
heterogeneity in these MR parameters was considerable in the four PDAC models. The images refer to a central axial section of the tumors, whereas 
the frequency distributions are based on the individual voxel values of all tumor sections. Color bars ADC, ve, and K
trans scales. Scale bars 2 mm. Verti-
cal lines median values
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The possibility that ADC may be associated with ve has 
not been investigated in PDAC. However, several stud-
ies have attempted to show correlations between ADC 
and ve in other types of cancer, but significant correla-
tions have not been found in any study thus far [36–39]. 
In contrast, a significant correlation between ADC and ve 
was detected in the present study, possibly because both 
ADC and ve are strongly influenced by the extracellular 
matrix in PDAC xenografts. However, due to the nature 
of these MR parameters, it is likely that the distribution 
of collagen fibers has a stronger influence on ADC than 
ve. It should be noticed that the two non-differentiated 
tumor models both showed a more dispersed collagen 
matrix and a higher total amount of collagen than the 
two differentiated tumor models. Moreover, the non-
differentiated tumor models grew more slowly than the 
differentiated ones, possibly because their growth rate 
was limited by the rate of collagen synthesis, and conse-
quently, both ADC and ve were found to decrease with 
increasing tumor volume doubling time.
Our study also showed that Ktrans differed significantly 
among the four PDAC models, but in contrast to ADC 
and ve, this parameter did not differ between the differen-
tiated and non-differentiated models. Ktrans is a parame-
ter that is influenced primarily by tumor blood perfusion 
and vessel wall permeability [28, 32]. Because BxPC-3 
showed high Ktrans values and Capan-2 showed low val-
ues of Ktrans, it is not likely that tumor perfusion plays 
a significant role in the differentiation of PDAC. Fur-
thermore, significant correlations were found between 
Ktrans on the one hand and ADC, ve, and Td on the other. 
However, these correlations appeared primarily because 
the BxPC-3 tumors showed substantially higher Ktrans 
values than the tumors of the other models, and the 
Fig. 6 Relationships between ADC, Ktrans, ve, and Td of differentiated and non‑differentiated PDAC tumor models. ADC, ve, and K
trans (a), ADC vs ve, 
ADC vs Ktrans, and Ktrans vs ve (b), and ADC vs Td, ve vs Td, and K
trans vs Td (c) for BxPC‑3, Capan‑2, MIAPaCa‑2, and Panc‑1 tumors. The relationships in (b) 
and (c) are statistically significant. Columns mean of the median value of 12–16 tumors. Error bars SEM. Points individual tumors. Linear curves regres‑
sion lines
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biological significance of these correlations may therefore 
be limited.
The study reported here has significant clinical impli-
cations. The potential of DW-MRI and DCE-MRI as 
methods for distinguishing between well and poorly dif-
ferentiated PDACs has been addressed in several clini-
cal studies, however, with conflicting results [17–19, 40]. 
Some studies have suggested that DCE-MRI may have 
prognostic power and thus may predict survival in PDAC 
patients, and furthermore, that DW-MRI may have the 
power to detect non-differentiated PDAC tumors with 
dense fibrosis [17, 40]. However, other studies have not 
shown similar relationships and thus do not support 
these suggestions [18, 19]. This discrepancy has raised 
doubt about the usefulness of parametric MR images in 
the diagnostics of PDAC; however, the discrepancy may 
be caused by several conditions, including low num-
ber of patients and inadequate scanning protocols (e.g., 
DW-MRI with only two b values) in some investigations. 
The present preclinical study indeed suggests that both 
DW-MRI and DCE-MRI have the power to discriminate 
between well differentiated and poorly differentiated 
tumors, and moreover, that these imaging methods may 
complement one another in the diagnostics of PDAC.
Conclusions
Both DW-MRI and DCE-MRI have the power to dis-
criminate between differentiated and non-differentiated 
PDAC xenografts, partly because the collagen content 
is higher in non-differentiated than in differentiated 
tumors. PDAC patients having developed non-differenti-
ated and/or collagen-rich primary tumors have particu-
larly poor prognosis, and it is likely that low ADC and 
low ve values are characteristic features of the tumors of 
these patients. Consequently, DW-MRI and DCE-MRI 
are noninvasive imaging methods with an added joint 
potential that should be taken advantage of in the diag-
nostics of PDAC.
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